Podcasts & White Papers

More from the Exploristics team

Interviews

Simulations: Your Most Powerful Study Design Tool

Exploristics CDSO Kim Hacquoil and Statistical Consulting Team Lead Jamie Inshaw join Alexander Schacht on his Effective Statistician podcast to discuss the benefit of using simulation in study design.

Impactful Authenticity: Spinning Plates

Exploristics CDSO, Kim Hacquoil joins Lucy Rowell for the latest Impactful Authenticity podcast to discuss her career.

The Theory of the Postdoc Evolution, QUB PDC Podcast

Data Strategy Team Lead, Dr Sheila McCartan joins Dr Claire Tonry to discuss moving from academia to industry.

The Effective Statistician, Small pond big fish

Exploristics CDSO, Kim Hacquoil, joins Alexander Schacht on his podcast to discuss working as a statistician in a smaller company after moving from large Pharma.

The Effective Statistician

Exploristics CEO, Aiden Flynn, joins Alexander Schacht on his Effective Statistician podcast to discuss the power of simulation in designing clinical studies.

Common Causes of Clinical Trial Failures

A discussion with Matthew Cardinal from Halloran Consulting Group.

People Always, Patients Sometimes

Exploristics’ CEO discusses how data simulation studies can reduce the risk and costs of clinical trials.

Webinars

Webinar July 2023: Designing the study you actually want! Matching trial objectives to design via the Estimands framework.

Learn more on how using the estimand framework ensures study objectives are aligned with design for more successful studies.

Webinar June 2023: Do more with less: gain valuable insights from a constrained setting

How incorporating repeated measurements into study design can improve the probability of success for clinical trials with constrained settings such as small populations.

Webinar May 2023: I’ve got the power. Or have I?

High power does not always mean high probability of success. Learn more on how removing tunnel vision on power can reduce study failure.

Webinar May 2023: I just need a simple sample size.

A sample size estimate can pose more questions than it answers. Learn more on why sample size is just the first step in a more holistic approach to study design.

Webinar May 2023: Can Pharma learn from development in other industries?

Industries such as car manufacturing successfully integrate technologies like simulation into product development to increase efficiency.

Webinar October 2022: Why do correlations matter in clinical trial design?

Many trial designs are over simplistic and don’t fully consider the inter-relationships between study factors that can impact outcomes.

Webinar June 2022: Introducing KerusCloud 2022

Most clinical trials fail, but simulations are revolutionising study design to improve success rates. Get ahead of the curve to learn more about this game changing approach!

Interviews

Simulation – your most powerful study design tool
Simulations: Your Most Powerful Study Design Tool

Exploristics CDSO Kim Hacquoil and Statistical Consulting Team Lead Jamie Inshaw join Alexander Schacht on his Effective Statistician podcast to discuss the benefit of using simulation in study design

Impactful Authenticity: Spinning Plates
Impactful Authenticity: Spinning Plates

Exploristics CDSO, Kim Hacquoil joins Lucy Rowell for the latest Impactful Authenticity podcast to discuss her career.

The Theory of the Postdoc Evolution, QUB PDC Podcast
The Theory of the Postdoc Evolution, QUB PDC Podcast

Data Strategy Team Lead, Dr Sheila McCartan joins Dr Claire Tonry to discuss moving from academia to industry.

The Effective Statistician, Small pond big fish
The Effective Statistician, Small pond big fish

Exploristics CDSO, Kim Hacquoil, joins Alexander Schacht on his podcast to discuss working as a statistician in a smaller company after moving from large Pharma.

The Effective Statistician
The Effective Statistician

Exploristics CEO, Aiden Flynn, joins Alexander Schacht on his Effective Statistician podcast to discuss the power of simulation in designing clinical studies.

Common Causes of Clinical Trial Failures
Common Causes of Clinical Trial Failures

A discussion with Matthew Cardinal from Halloran Consulting Group.

exploristics spencer health solutions
People Always, Patients Sometimes

Exploristics’ CEO discusses how data simulation studies can reduce the risk and costs of clinical trials.

Webinars

Webinar July 2023: Designing the study you actually want! Matching trial objectives to design via the Estimands framework.

Learn more on how using the estimand framework ensures study objectives are aligned with design for more successful studies.

Webinar June 2023: Do more with less: gain valuable insights from a constrained setting

How incorporating repeated measurements into study design can improve the probability of success for clinical trials with constrained settings such as small populations.

Webinar May 2023: I’ve got the power. Or have I?

High power does not always mean high probability of success. Learn more on how removing tunnel vision on power can reduce study failure.

Webinar May 2023: I just need a simple sample size.

A sample size estimate can pose more questions than it answers. Learn more on why sample size is just the first step in a more holistic approach to study design.

Webinar May 2023: Can Pharma learn from development in other industries?

Industries such as car manufacturing successfully integrate technologies like simulation into product development to increase efficiency.

Webinar October 2022: Why do correlations matter in clinical trial design?

Many trial designs are over simplistic and don’t fully consider the inter-relationships between study factors that can impact outcomes.

Webinar June 2022: Introducing KerusCloud 2022

Most clinical trials fail, but simulations are revolutionising study design to improve success rates. Get ahead of the curve to learn more about this game changing approach!

White Papers

White Papers

Estimands – opportunity or risk for drug developers?

The estimand framework helps to align study objectives with design. Here, we give an overview of the rationale, definitions and the impact evaluating estimands could have on clinical trial design.

Why thinking big for small populations is transforming rare disease drug development
Why thinking big for small populations is transforming rare disease drug development

Individuals with rare and orphan diseases face substantial unmet clinical need and so there is a demand for continued improvements in the way we approach drug development in this setting.

Whitepaper-Synthetic-Control-Arm
Are Synthetic Control Arms the Future Standard in Clinical Trials?

The role of non-randomized evidence in clinical studies, drug development, and healthcare decision-making is rapidly expanding. Here we give an overview of how synthetic controls can add value to clinical studies, and the emerging methodologies used in constructing and analysing synthetic controls.

Better Adherence, Higher Engagement
Better Adherence, Higher Engagement:
Finding The Clinical Trials Sweet Spot

Clinical trial sponsors and clinical research organizations must work through an ever-expanding set of challenges to ensure their studies of new drugs produce valid results. And they must do so while strictly managing costs and timelines. As more trials make use of inhome settings, digital technologies and realtime patient data, the pressure increases to efficiently manage a process that’s dramatically different from the traditional methods of direct observation inside the walls of a clinic.

exploristics scendea engaging with regulation on novel statistical approaches to clinical development
Engaging With Regulators On Novel Statistical Approaches To Clinical Development

The Pharmaceutical Industry is undergoing significant change as it faces extreme pressure to deliver new treatments to market at a time of increased spending in R&D. Multiple economic pressures are being exerted on the industry, ranging from an impending patent cliff, a decrease in income due to greater competition from generics and biosimilars, to demands on drug pricing by governments.

Want to find out more? Get in touch.

    Click here to join our mailing list for occasional company updates.